{"ATC Code":"N05BA16","Abbreviation":"","Aliases":["Nordiazepam","desmethyldiazepam","Norprazepam","N-Desmethyldiazepam","Calmday","N-Demethyldiazepam","N-Deoxydemoxepam","Madar","1-Demethyldiazepam","N1-Desmethyldiazepam"],"CAS":"1088-11-5","ChEBI":"CHEBI:111762","ChEMBL":"CHEMBL523","ChemicalClasses":["benzodiazepine"],"Chirality":"achiral","Classes":null,"DEA no":2838,"DrugClasses":[],"EINECS":"214-123-4","EliminationHalfLife":"36-200 hours\u003ca href='#cite_note-4'\u003e\u003csup\u003e[4]\u003c/sup\u003e\u003c/a\u003e","European Community (EC) Number":"214-123-4","HMDB ID":"HMDB0060538","HeavyAtomCount":19,"Human Drugs":"Pharmaceuticals","IUPACName":"7-chloro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one","InChI":"InChI=1S/C15H11ClN2O/c16-11-6-7-13-12(8-11)15(17-9-14(19)18-13)10-4-2-1-3-5-10/h1-8H,9H2,(H,18,19)","InChIKey":"AKPLHCDWDRPJGD-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)","MolecularFormula":"C\u003csub\u003e15\u003c/sub\u003eH\u003csub\u003e11\u003c/sub\u003eClN\u003csub\u003e2\u003c/sub\u003eO","MolecularWeight":"270.71 g/mol","PrevSalts":[],"PubChemId":2997,"Record Description":["Nordazepam is a 1,4-benzodiazepinone having phenyl and chloro substituents at positions 5 and 7 respectively; it has anticonvulsant, anxiolytic, muscle relaxant and sedative properties but is used primarily in the treatment of anxiety. It has a role as a GABA modulator, an anxiolytic drug, an anticonvulsant, a sedative and a human metabolite. It is a 1,4-benzodiazepinone and an organochlorine compound.","Nordiazepam is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance.","An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.","Nordazepam has been reported in Solanum tuberosum, Glycine max, and other organisms with data available.","NORDAZEPAM is a small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.","Nordiazepam is a metabolite of Diazepam. Diazepam, first marketed as Valium by Hoffmann-La Roche, is a benzodiazepine drug. Nordazepam, also known as desoxydemoxepam, nordiazepam and desmethyldiazepam, is a 1,4-benzodiazepine derivative. Like other benzodiazepine derivatives, it has anticonvulsant, anxiolytic, muscle relaxant and sedative properties. (Wikipedia)","An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.","Nordazepam is a 1,4-benzodiazepinone having phenyl and chloro substituents at positions 5 and 7 respectively; it has anticonvulsant, anxiolytic, muscle relaxant and sedative properties but is used primarily in the treatment of anxiety. It has a role as a GABA modulator, an anxiolytic drug, an anticonvulsant, a sedative and a human metabolite. It is a 1,4-benzodiazepinone and an organochlorine compound."],"RefCount":5,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Nordazepam","Name":"Nordazepam","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q3180288","Name":"Nordazepam","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB14028","Name":"Nordazepam","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/2997","Name":"Nordazepam","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL523","Name":"Nordazepam","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:111762","Name":"Nordazepam","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=1088-11-5","Name":"Nordazepam","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0060538","Name":"Nordazepam","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07486","Name":"Nordazepam","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/67220MCM01","Name":"Nordazepam","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID2049000","Name":"Nordazepam","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 2997, Nordazepam. Accessed June 25, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/2997\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/2997\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Nordazepam. UNII: 67220MCM01. Global Substance Registration System. Accessed June 25, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/67220MCM01\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/67220MCM01\u003c/a\u003e","Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. March 31, 2023. Accessed June 25, 2025. \u003ca href=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003ehttps://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003c/a\u003e","Ashton CH. Benzodiazepine Equivalence Table. benzo.org.uk. March 1, 2007. Accessed June 25, 2025. \u003ca href=http://www.benzo.org.uk/bzequiv.htm\u003ehttp://www.benzo.org.uk/bzequiv.htm\u003c/a\u003e"],"SMILES":"C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3","Scheduling":[{"gov":"Brazil","ref":["3"],"schedule":"B1 substance"},{"gov":"Canada","ref":[],"schedule":"Schedule IV substance"},{"gov":"Germany","ref":[],"schedule":"prescription only/Anlage III substance"},{"act":"Controlled Substances Act (CSA)","gov":"United States","ref":[],"schedule":"Schedule I"}],"Solubility":"\u003e40.6 [ug/mL] (The mean of the results at pH 7.4)","StoreUNII":["67220MCM01"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="91.494mm" version="1.2" viewBox="0 0 84.043 91.494" width="84.043mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="92.0" stroke="none" width="85.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="78.299" x2="71.695" y1="28.691" y2="14.975"/>
                  
            <g class="bond" id="mol1bnd2">
                        
                <line x1="70.379" x2="77.799" y1="14.668" y2="5.406"/>
                        
                <line x1="72.282" x2="79.702" y1="16.193" y2="6.931"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="77.799" x2="74.089" y1="5.405999999999999" y2="10.036999999999999"/>
                <line class="hi" stroke="#FF0D0D" x1="79.702" x2="75.99199999999999" y1="6.931000000000001" y2="11.562000000000001"/>
            </g>
                  
            <line class="bond" id="mol1bnd3" x1="71.695" x2="60.166" y1="14.975" y2="12.29"/>
                  
            <line class="bond" id="mol1bnd4" x1="53.83" x2="44.975" y1="13.957" y2="21.071"/>
                  
            <g class="bond" id="mol1bnd5">
                        
                <line x1="44.975" x2="44.975" y1="36.311" y2="21.071"/>
                        
                <line x1="42.536" x2="42.536" y1="34.903" y2="22.479"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd6" x1="44.975" x2="31.767" y1="36.311" y2="43.931"/>
                  
            <g class="bond" id="mol1bnd7">
                        
                <line x1="18.559" x2="31.767" y1="36.311" y2="43.931"/>
                        
                <line x1="20.997" x2="31.767" y1="34.903" y2="41.116"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd8" x1="18.559" x2="18.559" y1="36.311" y2="21.071"/>
                  
            <g class="bond" id="mol1bnd9">
                        
                <line x1="31.767" x2="18.559" y1="13.451" y2="21.071"/>
                        
                <line x1="31.767" x2="20.997" y1="16.266" y2="22.479"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd10" x1="44.975" x2="31.767" y1="21.071" y2="13.451"/>
                  
            <line class="bond" id="mol1bnd11" x1="18.559" x2="6.875" y1="36.311" y2="43.059"/>
                  
            <line class="bond" id="mol1bnd12" x1="44.975" x2="56.862" y1="36.311" y2="45.861"/>
                  
            <g class="bond" id="mol1bnd13">
                        
                <line x1="56.862" x2="68.391" y1="45.861" y2="43.176"/>
                        
                <line x1="57.464" x2="67.838" y1="43.217" y2="40.802"/>
                      
                <line class="hi" stroke="#3050F8" x1="68.391" x2="62.62650000000001" y1="43.176" y2="44.5185"/>
                <line class="hi" stroke="#3050F8" x1="67.838" x2="62.650999999999996" y1="40.802" y2="42.0095"/>
            </g>
                  
            <line class="bond" id="mol1bnd14" x1="78.299" x2="73.482" y1="28.691" y2="38.696"/>
                  
            <line class="bond" id="mol1bnd15" x1="56.862" x2="53.476" y1="45.861" y2="60.721"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="64.662" x2="53.476" y1="71.084" y2="60.721"/>
                        
                <line x1="61.971" x2="52.851" y1="71.916" y2="63.465"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd17" x1="64.662" x2="61.276" y1="71.084" y2="85.943"/>
                  
            <g class="bond" id="mol1bnd18">
                        
                <line x1="46.705" x2="61.276" y1="90.439" y2="85.943"/>
                        
                <line x1="47.331" x2="59.211" y1="87.694" y2="84.029"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd19" x1="46.705" x2="35.52" y1="90.439" y2="80.075"/>
                  
            <g class="bond" id="mol1bnd20">
                        
                <line x1="38.906" x2="35.52" y1="65.216" y2="80.075"/>
                        
                <line x1="40.97" x2="38.21" y1="67.131" y2="79.244"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd21" x1="53.476" x2="38.906" y1="60.721" y2="65.216"/>
                  
            <path class="atom" d="M83.483 3.078q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM79.62 3.078q-.0 .923 .387 1.459q.392 .53 1.22 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.459q.0 -.929 -.387 -1.452q-.381 -.524 -1.208 -.524q-.834 -.0 -1.226 .524q-.393 .523 -.393 1.452z" fill="#FF0D0D" id="mol1atm3" stroke="none"/>
                  
            <g class="atom" id="mol1atm4">
                        
                <path d="M58.802 13.97h-.72l-2.619 -4.066h-.03q.012 .238 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" stroke="none"/>
                        
                <path d="M58.666 8.509h-.62v-2.286h-2.512v2.286h-.613v-4.899h.613v2.071h2.512v-2.071h.62v4.899z" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M2.906 42.117q-.786 .0 -1.239 .53q-.452 .524 -.452 1.447q-.0 .911 .417 1.446q.422 .53 1.268 .53q.321 .0 .607 -.053q.291 -.06 .565 -.143v.536q-.274 .101 -.565 .148q-.292 .054 -.697 .054q-.744 -.0 -1.25 -.31q-.5 -.309 -.75 -.875q-.25 -.571 -.25 -1.339q.0 -.744 .268 -1.31q.274 -.565 .804 -.881q.529 -.321 1.279 -.321q.78 -.0 1.352 .285l-.244 .524q-.226 -.101 -.506 -.184q-.274 -.084 -.607 -.084zM5.662 46.541h-.601v-5.215h.601v5.215z" fill="#1FF01F" id="mol1atm11" stroke="none"/>
                  
            <path class="atom" d="M73.636 44.857h-.72l-2.62 -4.066h-.029q.012 .238 .029 .595q.024 .357 .024 .732v2.739h-.565v-4.9h.714l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.023 -.476q-.006 -.262 -.006 -.483v-2.768h.577v4.9z" id="mol1atm13" stroke="none"/>
                
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="60.166" x2="65.9305" y1="12.29" y2="13.6325"/>
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="60.166" x2="65.9305" y1="12.29" y2="13.6325"/>
            <line class="hi" id="mol1bnd4" stroke="#3050F8" x1="53.83" x2="49.4025" y1="13.957" y2="17.514000000000003"/>
            <line class="hi" id="mol1bnd4" stroke="#3050F8" x1="53.83" x2="49.4025" y1="13.957" y2="17.514000000000003"/>
            <line class="hi" id="mol1bnd11" stroke="#1FF01F" x1="6.875" x2="12.717" y1="43.059" y2="39.685"/>
            <line class="hi" id="mol1bnd14" stroke="#3050F8" x1="73.482" x2="75.8905" y1="38.696" y2="33.6935"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Title":"Nordazepam","UNII":"67220MCM01","Wikidata":"Q3180288","Wikipedia":"Nordazepam","XLogP":2.9}